ASX Announcements

Memphasys is committed to providing shareholders with complete, up-to-the-minute information about the Company. Contact, stock, and corporate information can be found in this section of the website and on the Australian Securities Exchange.

12 December 2024 Memphasys Signs Letter of Intent with HeranovaTM for FelixTM System Distribution in Greater China

29 November 2024 Second Supplementary Prospectus

22 November 2024 CEO Address to Shareholders

22 November 2024 Results of Memphasys Limited Annual General Meeting

21 November 2024 Memphasys Welcomes Lindley Edwards as Chair as commercialisation milestones advance

18 November 2024 Felix™ Clinical Trial Reaches 95% Completion

15 November 2024 Memphasys’ RoXsta™ System Secures Provisional Patent Approval and Publishes First Paper in Major International Journal

5 November 2024 SPP and Placement Completion

30 October 2024 Quarterly Activity Report and Appendix 4C

24 October 2024 Market Update – FelixTM System Clinical Trial Nears Completion, CE Mark Strategy to Accelerate European Market Entry

22 October 2024 Appendix 3B – Proposed issue of securities

22 October 2024 Extension of Share Purchase Plan Closing Date and Updates to Timetable for the Offers 

18 October 2024 Update to disclosure in Supplementary Prospectus – Placement participation

18 October 2024 Memphasys commences Three-Year Equine Fertility Study, with Commercial Outcomes from Felix™ System expected within 12 months

8 October 2024 Supplementary Prospectus 

25 September 2024 Notice of General Meeting

23 September 2024 Memphasys files patent for novel antioxidant assay system, RoXsta

20 September 2024 Target Market Determination (TMD)SPP Prospectus

16 September 2024 FelixTM System equine application on track for sales within 12 months following positive initial study results

12 September 2024 A$2.0 million capital raising to expedite FelixTM commercialisation activities and strategic partner discussions

4 September 2024 Strategic Equine Fertility Study to Support Global Commercialisation of a FelixTM Device

30 June 2024 Appendix 4E – Preliminary final report

31 July 2024 June 2024 Quarterly Activity Report and Appendix 4C – Memphasys Linited (ASX:MEM)

29 July 2024 Memphasys secures +$1M funding from major shareholder and R&D Tax Rebate loan

24 July 2024 Sales, Product Development and Clinical Trial Update

19 July 2024 Progress Update: Memphasys animal research / development activities – Oxidative Stress measurement to be immediate focus

6 June 2024 Executive Director Dr David Ali Appointed Full Time Chief Executive Officer

30 May 2024 Memphasys appoints highly experienced animal industry experts to expedite the commercialisation of its animal breeding products

20 May 2024 Felix™ technology provides clear benefits over widely used sperm preparation methods in a Japanese clinical trial

9 May 2024 Investor Presentation – Updated as  of 20th May 2024 Investor Presentation. Updated 3rd June Investor Presentation.

29 April 2024 March 2024 Quarterly Activity Report an Appendix 4C

18 March 2024 FelixTM System Sales Orders Accelerate in Japan

25 January 2024 AI-Port Update: Spring Field Trial Yields Positive Results

25 January 2024 Quarterly Activity Report and Appendix 4C – Memphasys Limited (ASX: MEM)

2 January 2024 Distribution agreement with Vitrolife expands – agreements now in place for Canada & NZ 

20231204 – 2023 Rights Issue Prospectus – Final ASX version – disclaimer must be accepted prior to access.

30 November Executive transition and Capital Raise

31 October 2023 Quarterly Activity Report and Appendix 4C

26 September 2023 Investor Presentation – September 2023, Human & Animal Programs

15 September 2023 FelixTM System successfully records 10 new live births in India

14 August 2023 Initial FelixTM System order placed by Vitrolife Japan

7 August 2023 Memphasys signs exclusive Japanese Felix TM distribution agreement with Vitrolife

28 July 2023 Quarterly Activities/Appendix 4C Cash Flow Report 

13 July 2023 New Patents granted for Felix System 

6 June 2023 Felix considered best method to treat cryopreserved semen 

28 April 2023 Quarterly Activities/Appendix 4C Cash Flow Report 

5 April 2023 Investor presentation April 2023 

3 April 2023 Japan first commercial sale and first baby born using Felix 

30 March 2023 Experienced fertility expert appointed Operations Director 

28 February 2023 Highly-credentialled exec appointed as Director of BusDev 

24 February 2023 Half Yearly Report and Accounts 

7 February 2023 KOL testings demonstrate Felix System outperforms DGC 

31 January 2023 December Quarterly Activities/Appendix 4C Cash Flow Report 

27 October 2022 September Quarterly Activities/Appendix 4C Cash Flow Report

25 October 2022 Notice of Annual General Meeting/Proxy Form 

24 October 2022 FELIX System commercialisation, regulatory plan and trial

21 September 2022 Appendix 2A- Application for Quotation of Securities

19 September 2022 Rights Issue Closure and Shortfall Notification

5 September 2022 Non-Renounceable Issue

5 September 2022 Appendix 3B 

31 August 2022 Full Year Statutory Accounts

31 August 2022 Preliminary Final Report

31 August 2022 Appendix 4G and Corporate Governance Statement

29 August 2022 Rights Issue Prospectus despatched

25 August 2022 Application for quotation of securities

18 August 2022 Rights Issue offer – Letter to ineligible shareholders 

18 August 2022 Non-Renounceable IssueWebsite Disclaimer

18 August 2022 Update – Proposed issue of securities – MEM

17 August 2022 Proposed issue of securities – MEM

17 August 2022 Reinstatement to Official Quotation

17 August 2022 $3.36 capital raising to accelerate FELIX commercialisation

11 August 2022 Court Orders Granted and update on Proposed Capital Raising

2 August 2022 Cleansing Statement 

29 July 2022 Quarterly Activities/Appendix 4C Cash Flow Report 

29 July 2022 Suspension from Official Quotation

27 July 2022 Trading Halt 

28 June 2022 Monash IVF clinical study enrols first patient using FELIX

27 June 2022 Notification of cessation of securities – MEM

9 June 2022 Felix System commercialisation update

6 June 2022 Notification of cessation of securities – MEM

17 May 2022 Response to ASX Query

26 April 2022 Final Director’s Interest Notice SH

26 April 2022 Initial Director’s Interest Notice – RC

26 April 2022 Non-Exec Chair Appointment and Director Resignation

12 April 2022 Quarterly Activities/Appendix 4C Cash Flow Report 

3 Mar 2022 Creating Novel fertility Solutions

25 Jan 2022 Quarterly Activities/Appendix 4C Cash Flow Report 

24 Jan 2022  Change of Directors Interest Notice

19 Jan 2022  Sale of existing Convertible Note to Peters Investments Pty Ltd

20 Dec 2021  Memphasys secures first Felix™ System commercial sale for clinical IVF use

9 Dec 2021  Memphasys & Monash IVF to commence clinical trial of Felix™ system to support regulatory applications and commercial sales

2 Dec 2021  Field data collection successfully completed using the prototype Samson stallion fertility diagnostic device

9 Oct 2021  Change of director’s interest notice

28 Sep 2021  Cleansing Notice – Section 708A(5)(e)

28 Sep 2021  Application for quotation of securities – MEM

20 Sep 2021  Acceleration of reproductive biotechnology portfolio

17 Sep 2021  Appendix 3G correction

17 Sep 2021  Notification regarding unquoted securities

10 Sep 2021  Change of Director’s Interest Notice – AC and AG

3 Sep 2021  Appendix 3G

1 Sep 2021  Notification regarding unquoted securities – MEM

1 Sep 2021  MEM reaches settlement agreement with Hydrix

31 Aug 2021  Commercial arrangement between Hydrix and Memphasys 

31 Aug 2021  FY21 Corporate Governance Statement and Appendix 4G

30 Aug 2021  FY21 Full Year Statutory Accounts

30 Aug 2021  Preliminary Final Report

24 Aug 2021  Results of General Meeting

20 Aug 2021  General Meeting to be held as a Virtual Meeting of members 

30 Jul 2021  Disclosure Document – Cleansing Notice

30 Jul 2021  Application for quotation of securities – MEM

30 Jul 2021  Notification regarding unquoted securities – MEM 

26 Jul 2021  Quarterly Activities/Appendix 4C Cash Flow Report

23 Jul 2021  Notice of General Meeting/Proxy Form

5 Jul 2021  Global andrology expert, Professor John Aitken, joins MEM

1 Jul 2021  Upgraded Felix Device verification passed

26 May 2021  Proposed issue of Securities – MEM

26 May 2021  Memphasys completes $3m capital raise

25 May 2021  Trading Halt

4 May 2021  Assisted reproductive biotechnology products update

4 May 2021  Prof. John Aitken receives distinguished andrology award

30 Apr 2021  Quarterly Cashflow Report

29 Apr 2021  Granted US patents strengthens IP portfolio

27 Apr 2021  Felix device – V&V progress and KOL study update

30 Mar 2021  FELIX device Verification and Validation process update

8 Mar 2021  Felix device validation testing delayed

26 Feb 2021  Half Yearly Report and Accounts

17 Feb 2021  Change of Director’s Interest Notice – Coutts

17 Feb 2021  Cancellation of Performance Options

2 Feb 2021  Disclosure Document – s708A cleansing notice

2 Feb 2021  Appendix 2A option conversion